BeOne Medicines Ltd.
BEIGF$40.93B
Large CapNASDAQBiotechnology🇺🇸North America11.0K employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Nov 15, 2026
35wMarket Overview
Stock performance and key metrics
BEIGF News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
Sonrotoclax
Waldenstrom Macroglobulinemia
Zanubrutinib
Chronic Lymphocytic Leukemia
BGB-16673
B-cell Malignancy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonrotoclax | Phase 3 | Waldenstrom Macroglobulinemia | - | - |
Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
BGB-16673 | Phase 2 | B-cell Malignancy | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply